TRPV1 antagonists

1. A compound having formula (I)

or a pharmaceutically acceptable salt thereof, wherein

R 1 represents a group of formula (a), (b), (c), or (d)

R x , at each occurrence, represents optional substituent(s) on any substitutable position of the bicyclic ring and is selected from the group consisting of alkyl, halogen, haloalkyl, OH, O(alkyl), O(haloalkyl), NH 2 , N(H)(alkyl), and N(alkyl) 2 ;

R a is hydrogen or methyl;

R 2 and R 3 are the same or different and are each independently hydrogen, C 1 -C 5 alkyl, or haloalkyl; or

R 2 and R 3 , together with the carbon atom to which they are attached, form a C 3 -C 6 monocyclic cycloalkyl ring, optionally substituted with 1, 2, or 3 substituents selected from the group consisting of alkyl and halogen;

R 4 , at each occurrence, represents optional substituent(s) on any substitutable position of the bicyclic ring and is selected from the group consisting of alkyl, halogen, haloalkyl, O(alkyl), O(haloalkyl), piperidinyl, and SCF 3 ; and

m and n are each independently 0, 1, 2, or 3;

with the proviso that the compound is other than

N-(7-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

N-isoquinolin-5-yl-N′-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

N-1H-indazol-4-yl-N′-(6-methyl-3,4-dihydro-2H-chromen-4-yl)urea;

N-isoquinolin-5-yl-N′-(6-methyl-3,4-dihydro-2H-chromen-4-yl)urea;

N-(6-fluoro-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(6-fluoro-3,4-dihydro-2H-chromen-4-yl)-N′-isoquinolin-5-ylurea;

N-(6-chloro-7-methyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(6-chloro-7-methyl-3,4-dihydro-2H-chromen-4-yl)-N′-isoquinolin-5-ylurea;

N-3,4-dihydro-2H-chromen-4-yl-N′-1H-indazol-4-ylurea;

N-(7-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N′-(3-methylisoquinolin-5-yl)urea;

N-(6-fluoro-3,4-dihydro-2H-chromen-4-yl)-N′-(3-methylisoquinolin-5-yl)urea;

N-(6-methyl-3,4-dihydro-2H-chromen-4-yl)-N′-(3-methylisoquinolin-5-yl)urea;

N-isoquinolin-5-yl-N′-(8-piperidin-1-yl-3,4-dihydro-2H-chromen-4-yl)urea;

N-3,4-dihydro-2H-chromen-4-yl-N′-isoquinolin-5-ylurea;

(+)-N-isoquinolin-5-yl-N′-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

(−)-N-isoquinolin-5-yl-N′-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

N-1H-indazol-4-yl-N′-[8-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

(−)-N-1H-indazol-4-yl-N′-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

(+)-N-1H-indazol-4-yl-N′-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

N-1H-indazol-4-yl-N′-(8-piperidin-1-yl-3,4-dihydro-2H-chromen-4-yl)urea;

N-(8-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-[8-chloro-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-1H-indazol-4-ylurea;

(+)-N-(8-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

(−)-N-(8-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-[8-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]urea;

N-[8-fluoro-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-[7-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]urea;

N-(6-fluoro-2-methyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-(7-methoxy-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)urea;

N-1H-indazol-4-yl-N′-(7-methoxy-2,2,8-trimethyl-3,4-dihydro-2H-chromen-4-yl)urea;

N-1H-indazol-4-yl-N′-(2,2,8-trimethyl-3,4-dihydro-2H-chromen-4-yl)urea;

N-1H-indazol-4-yl-N′-(7-methoxy-2,2-dimethyl-8-propyl-3,4-dihydro-2H-chromen-4-yl)urea;

N-(2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(7-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(7-fluoro-2,2-diethyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(7,8-difluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(7-(3,3-dimethylbutyl)-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(7-tert-butyl-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(2,2-diethyl-7-fluoro-3,4-dihydro-2H-chromen-4-yl)-N′-(1-methyl-1H-indazol-4-yl)urea;

N-(7,8-difluoro-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(7-fluoro-2,2-dipropyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(2,2-dibutyl-7-fluoro-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(2-tert-butyl-7-fluoro-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(2-tert-butyl-7-fluoro-3,4-dihydro-2H-chromen-4-yl)-N′-(1-methyl-1H-indazol-4-yl)urea;

N-(8-tert-Butyl-3,4-dihydro-2H-chromen-4-yl)-N′-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-(7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-(6-methyl-3,4-dihydro-2H-chromen-4-yl)urea;

N-[(4R)-3,4-Dihydro-2H-chromen-4-yl]-N′-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-[(4S)-3,4-Dihydro-2H-chromen-4-yl]-N′-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

1-(1H-indazol-4-yl)-3-(spiro[chroman-2,1′-cyclohexane]-4-yl)urea;

1-(7-fluorospiro[chroman-2,1′-cyclohexane]-4-yl)-3-(1H-indazol-4-yl)urea;

1-(7-fluorospiro[chroman-2,1′-cyclobutane]-4-yl)-3-(1H-indazol-4-yl)urea;

1-(7-fluorospiro[chroman-2,1′-cyclobutane]-4-yl)-3-(1-methyl-1H-indazol-4-yl)urea;

1-(6,7-dimethylspiro[chroman-2,1′-cyclohexane]-4-yl)-3-(1H-indazol-4-yl)urea;

1-(6,8-dichlorospiro[chroman-2,1′-cyclohexane]-4-yl)-3-(1H-indazol-4-yl)urea;

1-(6-chlorospiro[chroman-2,1′-cyclohexane]-4-yl)-3-(1H-indazol-4-yl)urea;

1-(7-tert-butylspiro[chroman-2,1′-cyclobutane]-4-yl)-3-(1H-indazol-4-yl)urea;

1-(6,8-difluorospiro[chroman-2,1′-cyclohexane]-4-yl)-3-(1H-indazol-4-yl)urea;

1-(6-ethoxyspiro[chroman-2,1′-cyclohexane]-4-yl)-3-(1H-indazol-4-yl)urea;

1-(1H-indazol-4-yl)-3-(6-methylspiro[chroman-2,1′-cyclopentane]-4-yl)urea;

1-(7-ethoxyspiro[chroman-2,1′-cyclopentane]-4-yl)-3-(1H-indazol-4-yl)urea;

1-(6,7-dimethylspiro[chroman-2,1′-cyclopentane]-4-yl)-3-(1H-indazol-4-yl)urea;

1-(7-fluorospiro[chroman-2,1′-cyclohexane]-4-yl)-3-(1-methyl-1H-indazol-4-yl)urea;

1-(1-methyl-1H-indazol-4-yl)-3-(spiro[chroman-2,1′-cyclohexane]-4-yl)urea;

1-(1H-indazol-4-yl)-3-(7-methoxyspiro[chroman-2,1′-cyclohexane]-4-yl)urea;

(±)1-(3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(7-chloro-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(6-bromo-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(6-methoxy-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(7-methoxy-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(6-methyl-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(7-methoxy-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)-3-(1-methylisoquinolin-5-yl)urea;

(±)1-(6-bromo-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)-3-(1-methylisoquinolin-5-yl)urea;

(±)1-(6-methyl-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)-3-(1-methylisoquinolin-5-yl)urea;

(±)1-(3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)-3-(1-methylisoquinolin-5-yl)urea;

(±)1-(3,4-dihydro-spiro-[2H-1-benzopyran-2,1′-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(+)1-(3,4-dihydro-spiro-[2H-1-benzopyran-2,1′-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(−)1-(3,4-dihydro-spiro-[2H-1-benzopyran-2, 1‘-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(3,4-dihydro-spiro-[2H-1-benzopyran-2, 1’-cyclobutan]-4-yl)-3-(8-chloroisoquinolin-5-yl)urea;

(±)1-(3,4-dihydro-spiro-[2H-1-benzopyran-2, 1‘-cyclobutan]-4-yl)-3-(3-methylisoquinolin-5-yl)urea;

(±)1-(3,4-dihydro-spiro-[2H-1-benzopyran-2, 1’-cyclobutan]-4-yl)-3-(1-methylisoquinolin-5-yl)urea;

(±)1-(3,4-dihydro-6-methyl-spiro-[2H-1-benzopyran-2, 1‘-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(3,4-dihydro-7-methyl-spiro-[2H-1-benzopyran-2, 1’-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(3,4-dihydro-6-fluoro-spiro-[2H-1-benzopyran-2,1′-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(+)1-(3,4-dihydro-6-fluoro-spiro-[2H-1-benzopyran-2,1′-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(−)1-(3,4-dihydro-6-fluoro-spiro-[2H-1-benzopyran-2,1′-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(3,4-dihydro-7-methoxy-spiro-[2H-1-benzopyran-2,1′-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

1-(6,8-difluoro-3,4-dihydro-spiro-[2H-1-benzopyran-2, 1‘-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(8-chloro-3,4-dihydro-spiro-[2H-1-benzopyran-2, 1’-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(3,4-dihydro-6-methoxy-spiro-[2H-1-benzopyran-2,1′-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(7-difluoromethoxy-3,4-dihydro-spiro-[2H-1-benzopyran-2, 1‘-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea hydrochloride;

(±)1-(7-difluoromethoxy-3,4-dihydro-spiro-[2H-1-benzopyran-2, 1’-cyclobutan]-4-yl)-3-(3-methylisoquinolin-5-yl)urea;

(±)1-(7-chloro-3,4-dihydro-spiro-[2H-1-benzopyran-2, 1‘-cyclobutan]-4-yl)-3-(3-methylisoquinolin-5-yl)urea;

(+)1-(6,8-difluoro-3,4-dihydro-spiro-[2H-1-benzopyran-2, 1’-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(−)1-(6,8-difluoro-3,4-dihydro-spiro-[2H-1-benzopyran-2,1′-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(3,4-dihydro-8-difluoromethoxy-spiro-[2H-1-benzopyran-2, 1‘-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(6-chloro-3,4-dihydro-spiro-[2H-1-benzopyran-2,1’-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(−)1-(6-chloro-3,4-dihydro-spiro-[2H-1-benzopyran-2,1′-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(6-bromo-3,4-dihydro-spiro-[2H-1-benzopyran-2,1′-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(6,8-dichloro-3,4-dihydro-spiro-[2H-1-benzopyran-2, 1‘-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(6-bromo-3,4-dihydro-7-methylspiro-[2H-1-benzopyran-2, 1’-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(6,7-dichloro-3,4-dihydro-spiro-[2H-1-benzopyran-2, 1‘-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(6-chloro-3,4-dihydro-7-methylspiro-[2H-1-benzopyran-2,1’-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(6-chloro-3,4-dihydro-spiro-[2H-1-benzopyran-2,1‘-cyclobutan]-4-yl)-3-(8-chloroisoquinolin-5-yl)urea;

(±)1-(6-fluoro-3,4-dihydro-spiro-[2H-1-benzopyran-2,1’-cyclobutan]-4-yl)-3-(8-chloroisoquinolin-5-yl)urea;

(±)1-(3,4-dihydro-6-fluoro-spiro-[2H-1-benzopyran-2,1′-cyclobutan]-4-yl)-3-(3-methylisoquinolin-5-yl)urea;

(±)1-(6-chloro-3,4-dihydro-spiro-[2H-1-benzopyran-2,1′-cyclobutan]-4-yl)-3-(3-methylisoquinolin-5-yl)urea;

(±)1-(6-chloro-3,4-dihydro-spiro-[2H-1-benzopyran-2,1′-cyclobutan]-4-yl)-3-(1-methylisoquinolin-5-yl)urea;

(±)1-(3,4-dihydro-6-fluoro-spiro-[2H-1-benzopyran-2,1′-cyclobutan]-4-yl)-3-(1-methylisoquinolin-5-yl)urea;

(±)1-(7-chloro-3,4-dihydro-spiro-[2H-1-benzopyran-2,1′-cyclobutan]-4-yl)-3-(isoquinolin-5-yl)urea;

(±)1-(3,4-dihydrospiro[chromene-2,1′-cyclobutan]-4-yl)-3-(1H-indazol-4-yl)urea;

(−)-1-(3,4-dihydrospiro[chromene-2,1′-cyclobutan]-4-yl)-3-(1H-indazol-4-yl)urea;

(+)-1-(3,4-dihydrospiro[chromene-2,1′-cyclobutan]-4-yl)-3-(1H-indazol-4-yl)urea;

(±)1-(6-fluoro-3,4-dihydrospiro[chromene-2,1′-cyclobutan]-4-yl)-3-(1H-indazol-4-yl)urea;

(±)1-(7-fluoro-3,4-dihydrospiro[chromene-2,1′-cyclobutan]-4-yl)-3-(1H-indazol-4-yl)urea;

(±)1-(6,8-difluoro-3,4-dihydrospiro[chromene-2,1′-cyclobutan]-4-yl)-3-(1H-indazol-4-yl)urea;

(+)-1-(6,8-difluoro-3,4-dihydrospiro[chromene-2,1′-cyclobutan]-4-yl)-3-(1H-indazol-4-yl)urea;

(±)1-(1H-indazol-4-yl)-3-(7-methyl-3,4-dihydrospiro[chromene-2,1′-cyclobutan]-4-yl)urea;

(±)1-(1H-indazol-4-yl)-3-(7-methoxy-3,4-dihydrospiro[chromene-2,1′-cyclobutan]-4-yl)urea;

(±)1-(1H-indazol-4-yl)-3-(7-chloro-3,4-dihydrospiro[chromene-2,1′-cyclobutan]-4-yl)urea;

(±)1-(3,4-dihydrospiro[chromene-2,1′-cyclobutan]-4-yl)-3-(6-bromo-1H-indazol-4-yl)urea;

(±)1-(3,4-dihydrospiro[chromene-2,1′-cyclobutan]-4-yl)-3-(6-fluoro-1H-indazol-4-yl)urea;

(+)-1-(3,4-dihydrospiro[chromene-2,1′-cyclobutan]-4-yl)-3-(6-fluoro-1H-indazol-4-yl)urea;

(±)1-(3,4-dihydrospiro[chromene-2,1′-cyclobutan]-4-yl)-3-(6-methoxy-1H-indazol-4-yl)urea; or

(−)-1-(6,8-difluoro-3,4-dihydrospiro[chromene-2,1′-cyclobutan]-4-yl)-3-(1H-indazol-4-yl)urea.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein said compound produces a transient elevation of the core body temperature of a mammal.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein said compound produces a transient elevation of the core body temperature of a mammal of greater than or equal to about 0.5° C.

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein said compound produces a transient elevation of the core body temperature of a mammal from about equal to 0.5° C. to less than or equal to about 2.0° C.

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein said compound at a concentration of 3 μM blocks at least about 95% calcium flux caused by activation of human TRPV1 by addition of 1 μM capsaicin, and blocks greater than about 95% calcium flux caused by activation of human TPRV1 at pH 5.5.

6. The compound according to any one of claim 2 , 3 , 4 , or 5 , or a pharmaceutically acceptable salt thereof wherein R 2 and R 3 are the same or different and are each independently hydrogen, C 1 -C 5 alkyl, or haloalkyl.

7. The compound according to claim 6 , or a pharmaceutically acceptable salt thereof wherein R 2 and R 3 are the same or different and are each independently C 1 -C 5 alkyl or haloalkyl.

8. The compound according to claim 7 or a pharmaceutically acceptable salt thereof wherein

R 1 is formula (a);

m is 0, 1, or 2; and

R 4 is alkyl, halogen, haloalkyl, or O(haloalkyl).

9. The compound according to claim 7 or a pharmaceutically acceptable salt thereof wherein

R 1 is formula (b);

m is 0, 1, or 2; and

R 4 is alkyl, halogen, haloalkyl, or O(haloalkyl).

10. The compound according to claim 7 or a pharmaceutically acceptable salt thereof wherein

R 1 is formula (c);

m is 0, 1, or 2;

R x is alkyl, halogen, or NH 2 ; and

R 4 is alkyl, halogen, haloalkyl, O(haloalkyl), or piperidinyl.

11. The compound according to claim 7 or a pharmaceutically acceptable salt thereof wherein

R 1 is formula (d);

m is 0, 1, or 2; and

R 4 is alkyl, halogen, haloalkyl, or O(haloalkyl).

12. The compound according to any one of claim 2 , 3 , 4 , or 5 , or a pharmaceutically acceptable salt thereof wherein R 2 and R 3 , together with the carbon atoms to which they are attached, form a C 3 -C 6 monocyclic cycloalkyl ring, optionally substituted with 1, 2, or 3 substituents selected from the group consisting of alkyl and halogen.

13. The compound according to claim 12 or a pharmaceutically acceptable salt thereof wherein

R 1 is formula (a);

m is 0, 1 or 2; and

R 4 is alkyl, halogen, haloalkyl, or O(haloalkyl).

14. The compound according to claim 12 or a pharmaceutically acceptable salt thereof wherein

R 1 is formula (b);

m is 0, 1, or 2; and

R 4 is alkyl, halogen, haloalkyl, or O(haloalkyl).

15. The compound of claim 12 or a pharmaceutically acceptable salt thereof wherein

R 1 is formula (c);

R x is alkyl, halogen, or NH 2 ;

m is 0, 1, or 2; and

R 4 is alkyl, halogen, haloalkyl, O(haloalkyl), or piperidinyl.

16. The compound according to claim 12 or a pharmaceutically acceptable salt thereof wherein

R 1 is formula (d);

m is 0, 1, or 2; and

R 4 is alkyl, halogen, haloalkyl, or O(haloalkyl).

17. The compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

N-[(4R)-6-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N′-(1-methyl-1H-indazol-4-yl)urea;

N-[(4R)-6-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N′-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-6-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N′-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-6-fluoro-3,3′,4,4′-tetrahydro-2′H-spiro[chromene-2,1′-cyclobutan]-4-yl]-N′-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-6,8-difluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N′-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-7-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N′-(1-methyl-1H-indazol-4-yl)urea;

N-[(4R)-7-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N′-1H-indazol-4-ylurea;

N-[(4R)-7-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N′-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-7-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N′-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-2,2-dimethyl-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-(1-methyl-1H-indazol-4-yl)urea;

N-[(4R)-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N′-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-2,2-dimethyl-7-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]-N′-(1-methyl-1H-indazol-4-yl)urea;

N-[(4R)-2,2-dimethyl-7-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]-N′-isoquinolin-5-ylurea;

N-[(4R)-2,2-dimethyl-8-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-(1-methyl-1H-indazol-4-yl)urea;

N-[(4R)-2,2-dimethyl-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-isoquinolin-8-ylurea;

N-[(4R)-2,2-dimethyl-8-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-1H-indazol-4-ylurea;

N-[(4R)-2,2-diethyl-7-fluoro-3,4-dihydro-2H-chromen-4-yl]-N′-(1-methyl-1H-indazol-4-yl)urea;

N-[(4R)-2,2-diethyl-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-(1-methyl-1H-indazol-4-yl)urea;

N-[(4R)-2,2-diethyl-8-fluoro-3,4-dihydro-2H-chromen-4-yl]-N′-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-2,2-diethyl-6-fluoro-3,4-dihydro-2H-chromen-4-yl]-N′-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-(1-methyl-1H-indazol-4-yl)-N′-[(4R)-8-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

N-[(4R)-2,2-diethyl-6,8-difluoro-3,4-dihydro-2H-chromen-4-yl]-N′-(1-methyl-1H-indazol-4-yl)urea;

N-1H-indazol-4-yl-N′-[(4R)-8-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

N-[(4R)-2,2-diethyl-7-fluoro-3,4-dihydro-2H-chromen-4-yl]-N′-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-6-fluoro-2,2-dipropyl-3,4-dihydro-2H-chromen-4-yl]-N′-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-2,2-diethyl-6-fluoro-3,4-dihydro-2H-chromen-4-yl]-N′-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-2,2-diethyl-7-fluoro-3,4-dihydro-2H-chromen-4-yl]-N′-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-7-chloro-2,2-diethyl-3,4-dihydro-2H-chromen-4-yl]-N′-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-7-chloro-2,2-diethyl-3,4-dihydro-2H-chromen-4-yl]-N′-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-2,2-diethyl-8-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-(1-methyl-1H-indazol-4-yl)urea;

N-[(4R)-7-chloro-2,2-diethyl-3,4-dihydro-2H-chromen-4-yl]-N′-(1-methyl-1H-indazol-4-yl)urea;

N-(1-methyl-1H-indazol-4-yl)-N′-[(4R)-8-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]urea;

N-[(4R)-2,2-dimethyl-7-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]-N′-(3-methylisoquinolin-5-yl)urea;

N-[(4R)-2,2-diethyl-7-fluoro-3,4-dihydro-2H-chromen-4-yl]-N′-iso quinolin-8-ylurea;

N-[(4R)-2,2-diethyl-8-fluoro-3,4-dihydro-2H-chromen-4-yl]-N′-isoquinolin-8-ylurea;

N-[(4R)-7-fluoro-2,2-bis(fluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-(3-aminoisoquinolin-5-yl)-N′-[(4R)-2,2-dimethyl-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

N-[(4R)-2,2-bis(fluoromethyl)-7-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]-N′-(1-methyl-1H-indazol-4-yl)urea;

N-[(4R)-2,2-bis(fluoromethyl)-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-isoquinolin-8-ylurea;

N-[(4R)-8-fluoro-2,2-dimethyl-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-(3-methylisoquinolin-5-yl)urea;

N-[(4R)-8-tert-butyl-3,4-dihydro-2H-chromen-4-yl]-N′-(3-methylisoquinolin-5-yl)urea;

N-[(4R)-7-chloro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N′-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-7-chloro-2,2-bis(fluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-7-chloro-2,2-bis(fluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-8-fluoro-2,2-bis(fluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-8-chloro-7-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N′-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-8-chloro-7-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N′-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-2,2-bis(fluoromethyl)-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-7,8-difluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N′-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-2,2-dimethyl-7-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]-N′-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-[(4R)-2,2-dimethyl-7-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]-N′-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]urea;

N-(8-fluoro-2,2-dimethyl-7-piperidin-1-yl-3,4-dihydro-2H-chromen-4-yl)-N′-(3-methylisoquinolin-5-yl)urea;

N-[(4R)-2,2-dimethyl-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-(6-fluoro-3-methylisoquinolin-5-yl)urea;

N-[(2R,4R)-2-(fluoromethyl)-2-methyl-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-(3-methylisoquinolin-5-yl)urea;

N-[(2S,4R)-2-(fluoromethyl)-2-methyl-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-(3-methylisoquinolin-5-yl)urea.

18. A pharmaceutical composition comprising a compound of formula (I) according to any one of claim 2 , 3 , 4 , or 5 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

19. The pharmaceutical composition according to claims 18 further comprising one or more analgesic or one or more nonsteroidal anti-inflammatory drug, or a combination thereof.

20. A method for treating pain comprising administering a therapeutically effective amount of a compound of formula (I) according to any one of claim 2 , 3 , 4 , or 5 , or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

21. The method according to claim 20 further comprising the step of co-administering with one or more analgesic or with one or more nonsteroidal anti-inflammatory drug, or combination thereof.

22. The method according to claim 21 wherein the nonsteroidal anti-inflammatory drug is ibuprofen.

23. A method for treating incontinence, micturition disorder, renal colic, cystitis, stroke, multiple sclerosis, asthma, cough, chronic obstructive pulmonary disease (COPD), broncho-constriction, gastroesophageal reflux disease (GERD), dysphagia, ulcer, bladder overactivity, urinary incontinence, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, Crohn's disease, cancer chemotherapy-induced emesis, or obesity, comprising administering a therapeutically effective amount of a compound of formula (I) according to any one of claim 2 , 3 , 4 , or 5 , or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

24. A method for treating inflammatory states, comprising burns, rheumatoid arthritis and osteoarthritis, said method comprises administering a therapeutically effective amount of a compound of formula (I) according to any one of claim 2 , 3 , 4 , or 5 , or a pharmaceutically acceptable salt thereof, to a subject in need thereof.